EURURO Vol. 73 No. 1

and distant metastases.

Table 6

lists the summary of

evidence and recommendations for follow-up of UTUC.

Surveillance regimens are based on cystoscopy and

urinary cytology for

5 yr

[1,6] .

Bladder recurrence is not

a distant recurrence. When KSS is performed, the ipsilateral

upper urinary tract requires careful follow-up due to the

high risk of disease recurrence

[1] .

Despite endourological

improvements, follow-up after kidney-sparing management

is difficult, and frequent, repeated endoscopic procedures

are necessary. As done in BCa, a second look has been

proposed after KSS but is not yet routine practice

[56] .

Conclusions

The EAU guidelines contain information on the manage-

ment of individual patients according to a current

standardised approach. Urologists should take into account

the specific clinical characteristics of each patient when

determining the optimal treatment regimen, based on the

proposed risk stratification of these tumours.

Author contributions:

Morgan Rouprêt had full access to all the data in

the study and takes responsibility for the integrity of the data and the

accuracy of the data analysis.

Study concept and design:

Rouprêt.

Acquisition of data:

Rouprêt, Babjuk, Cowan, Compérat, Zigeuner.

Analysis and interpretation of data:

Rouprêt, Babjuk, Compérat, Zigeuner.

Drafting of the manuscript:

Rouprêt.

Critical revision of the manuscript for important intellectual content:

Rouprêt, Babjuk, Cowan, Compérat, Zigeuner, Sylvester, Burger, Gontero,

Van Rhijn, Mosta

d, Palou, Shariat.

Statistical analysis:

None.

Obtaining funding:

None.

Administrative, technical, or material support:

None.

Supervision:

Rouprêt.

Other:

None.

Financial disclosures:

Morgan Rouprêt certi

es that all con

icts of

interest, including speci

nancial interests and relationships and

liations relevant to the subject matter or materials discussed in the

manuscript (eg, employment/af

liation, grants or funding, consultan-

cies, honoraria, stock ownership or options, expert testimony, royalties,

or patents

led, received, or pending), are the following: Morgan Rouprêt

is a company consultant for Lilly, Ipsen, Astellas, Takeda, and Sano

Pasteur; and participates in trials for GSK. Marko Babjuk is a company

consultant for Bayer and Ipsen; receives company speaker honoraria

from Ferring and GSK; and participates in trials for Sotio. Richard

Zigeuner receives company speaker honoraria from Roche and Novartis;

receives fellowships and travel grants from Bayer Healthcare, P

zer,

Amgen, Novartis, and GSK; receives company grants and research

support from Bayer Healthcare, company speaker honoraria from GSK

and Amgen, fellowships and travel grants from Astellas and Takeda; and

is a company consultant for P

zer. Maximilian Burger is a company

consultant for Photocure ASA, Astellas, and Ipsen Pharma; receives

company speaker honoraria from Astellas, Springer, and Novartis; and

participates in trials for Photocure SA and Ipsen Pharma. Paolo Gontero is

a company consultant for Janssen and Cepheid; and receives company

speaker honoraria from Ipsen. Bas van Rhijn is a company consultant for

Astellas. A. Hugh Mosta

d is a company consultant for Kyowa Hakko UK,

participates in trials for MSD, and receives speaker honorarium from

Prostrakan. Joan Palou is a company consultant for Olympus and

participates in trials for General Electric. Shahrokh Shariat owns or co-

owns the following patents: Shariat S, Slawin K. Methods to determine

prognosis after therapy for prostate cancer. US patent 60/266,976. May

31, 2001. Shariat S, Lerner S, Slawin K. Methods to determine prognosis

after therapy for bladder cancer. US patent 675.003US1. June 1,

2001. Shariat S, Slawin K, Kattan M, Scardino P. Pre- and post-treatment

nomograms for predicting recurrence in patients with clinically localised

prostate cancer that includes the blood markers interlukin-6 soluble

receptor and transforming growth. 2002. Slawin K, Kattan M, Shariat S,

Stephenson A, Scardino P. Nomogram for predicting outcome of salvage

radiotherapy for suspected local recurrence of prostate cancer after

radical prostatectomy. 2003. Shariat S. Soluble fas: a promising novel

urinary marker for the detection of bladder transitional cell carcinoma

(UTSD: 1666). US patent in process. He is a company consultant for

Astellas, Olympus, Wolff, Ipsen, and Cepheid; receives company speaker

honoraria from Lilly, Astellas, Ipsen, Olympus, Wolff, and Janssen; and

participates in trials on NMP22 for Alere Inc. Eva Compérat, Nigel Cowan

and Richard J. Sylvester have nothing to disclose.

Funding/Support and role of the sponsor:

None.

References

[1]

Roupret M, Babjuk M, Comperat E, et al. European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 2015;68:868 – 79

[2] Bob Phillips CB, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M.

Since November 1998. Updated by Jeremy Howick March 2009. Ox-

ford Centre for Evidence-based Medicine Levels of Evidence (May

2009).

http://wwwcebmnet/indexaspx?o=1025

[3]

Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle- invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447 – 61

[4]

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7 – 30

[5]

Cosentino M, Palou J, Gaya JM, Breda A, Rodriguez-Faba O, Villavi- cencio-Mavrich H. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol 2013;31:141 – 5

[6]

Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat SF. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol 2012;61:1069 – 70

[7]

Li WM, Shen J, Li CC, et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in neph- roureterectomy for primary upper urinary tract urothelial carcino- ma. Eur Urol 2010;57:963 – 9

[8]

Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical neph- roureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115:1224 – 33

[9]

Shariat SF, Favaretto RL, Gupta A, et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2011;29:481 – 6

[10]

Roupret M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies in- volved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol 2008;54:1226 – 36.

[11]

Audenet F, Colin P, Yates DR, et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassi fi ed as sporadic according to a multi-institutional database analysis: proposal of patient-speci fi c risk identi fi cation tool. BJU Int 2012;110(11 Pt B): E583 – 9.

[12]

Acher P, Kiela G, Thomas K, O ’ Brien T. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non- polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int 2010;106:300 – 2.

E U R O P E A N U R O L O GY 7 3 ( 2 0 18 ) 111

–

1 2 2

120